DEA Bans Bizarre Chemical: CUMYL-PEGACLONE Joins Schedule I Ranks
Published Date: 5/13/2026
Rule
Summary
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
Analyzed Economic Effects
6 provisions identified: 2 benefits, 4 costs, 0 mixed.
Possession and Sale Now Illegal
As of May 13, 2026, CUMYL-PEGACLONE is placed in Schedule I. Retail sales of Schedule I controlled substances to the general public are not allowed, and possession or any handling not authorized by the Controlled Substances Act may lead to administrative, civil, or criminal penalties.
DEA Registration Required to Handle
If you manufacture, distribute, import, export, research, analyze, or possess CUMYL-PEGACLONE, you must be registered with DEA under 21 U.S.C. 822, 823, 957, and 958 and 21 CFR parts 1301 and 1312. Any person who currently handles CUMYL-PEGACLONE and is not registered may not continue to handle it as of May 13, 2026, unless DEA has approved a registration.
Surrender or Dispose Stocks if Not Registering
If you are unwilling or unable to obtain a Schedule I registration, you must surrender or transfer all quantities of CUMYL-PEGACLONE to a DEA-registered person before the effective date of this rule (May 13, 2026). Disposal must follow 21 CFR part 1317 and applicable Federal, State, local, and Tribal laws.
Registration Compliance: Security, Records, Quotas
DEA registrants handling CUMYL-PEGACLONE must follow Schedule I rules for security, employee screening, labeling and packaging, quotas for manufacture, initial and biennial inventories (including an initial inventory on the date the registrant first engages in handling and inventories every two years thereafter), recordkeeping and reporting, required order forms, and import/export controls.
Temporary Research Continuation Window
If on May 13, 2026 you are already registered to conduct research with another Schedule I substance, you may continue research on CUMYL-PEGACLONE provided you submit a completed application for registration or modification no later than 90 calendar days after May 13, 2026. If DEA serves an order to show cause proposing denial, you must stop research when the order is served unless you request a hearing; requested hearings are to be held on an expedited basis not later than 45 calendar days after the request.
DEA Finds No Significant Small-Entity Impact
DEA certified under the Regulatory Flexibility Act that this final rule will not have a significant economic impact on a substantial number of small entities. DEA notes there appear to be no legitimate marketed drug sources and no evidence of significant diversion from legitimate suppliers.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
2026-08517 — Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
Starting May 1, 2026, the DEA officially puts four new substances—4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA—into Schedule I, meaning they’re now illegal to make, sell, or use without special permission. This affects anyone handling these chemicals, including researchers and businesses, who must follow strict rules or face serious penalties. The move aims to keep communities safer by cracking down on these risky drugs.
2026-08176 — Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
Starting April 28, 2026, FDA-approved marijuana-based medicines move from the strictest drug category (Schedule I) to a less strict one (Schedule III). This change helps medical marijuana businesses get faster federal permits to make and sell these products legally. If you have a state medical marijuana license, you’ll find it easier and quicker to work with these medicines under new federal rules.
2026-08177 — Schedules of Controlled Substances: Rescheduling of Marijuana
The DEA is planning to move marijuana to Schedule III, which means it’s seen as less risky and easier to use medically. This change affects patients, doctors, and businesses, making marijuana more accessible and possibly boosting the market. A public hearing starts June 29, 2026, with chances to join by May 28, so get ready to have your say!
Previous / Next Documents
Previous: 2026-09565 — Modernizing Spectrum Sharing for Satellite Broadband
The FCC is updating how satellite companies share space in the sky to bring faster internet, especially to rural areas. They’re replacing old rules with smarter ones that let satellite operators work together and protect each other from interference. These changes kick in on July 13, 2026, helping American homes and businesses get better broadband without extra costs.
Next: 2026-09575 — Extension of Import Restrictions Imposed on Categories of Archaeological and Ethnological Material of Türkiye
The U.S. is extending import restrictions on certain ancient and cultural items from Türkiye until March 24, 2031. This means collectors, museums, and sellers need to keep following the rules to protect Türkiye’s heritage. The new rule kicks in on May 13, 2026, keeping the ban active for another five years without any new fees or costs.